Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

EJMCR. 2021; 5(1): 18-21


Shingles infection resulting from BCG treatment for bladder cancer: a case report

Vivian Wong, Diana M. Lopategui, Elias Atri, Akshay Bhandari.




Abstract
Cited by 0 Articles

Background: Bacillus Calmette-Guerin (BCG) bladder instillations have been long known to successfully treat non-muscle invasive bladder cancer. The objective of this report is to highlight the first case to our knowledge of Varicella Zoster virus (VZV) shingles reactivation to BCG.
Case presentation: An 80-year-old male with history of Parkinson’s disease and recurring high-grade T1 bladder cancer. Five days after first repeat BCG instillation, patient presented to the emergency room with a progressively worsening rash that started 1 day after treatment, characterized as VZV shingles reactivation. Intravenous acyclovir treatment produced rapid clinical improvement.
Conclusion: Reactivation of dormant VZV infection may be a reaction to BCG intravesical instillation. This is, to the authors’ knowledge, the first documented case of this complication. Although coincidence cannot be completely ruled out, the timing of this case and the context of immunosuppression-immunomodulation inherent to BCG therapy make causality plausible.

Key words: BCG, shingles, bladder cancer, adverse reaction, varicella zoster, case report






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.